Physician profile
Anthony I Nunez
NPI 1093745028
$4,786,992.46
in general payments reported to CMS, 2019-2025
22 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.89 · 2020: $958 · 2021: $164 · 2022: $176 · 2023: $457 · 2024: $4.7M · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $4.8M · Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $4,784,987.15 |
| Food and Beverage | $629.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,784,987.15 | 2024-2025 | |
| Intuitive Surgical, INC. | $816.37 | 2020-2021 | |
| Artivion, INC. | $463.40 | 2019-2024 | Cardiac Non-Synergraft, On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder, Photofix Decellularized Bovine Pericardium |
| Astrazeneca Pharmaceuticals Lp | $166.17 | 2022-2023 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $82.30 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.28 | 2019-2023 | Iclusig |
| Corcym INC | $51.80 | 2023 | Perceval |
| Ethicon US, LLC | $48.41 | 2019-2020 | |
| Akorn, INC. | $47.62 | 2020 | |
| Genzyme Corporation | $35.74 | 2022 | |
| Davol INC. | $31.06 | 2020-2021 | |
| Masimo Corporation | $30.26 | 2024 | Set and Rainbow Set |
| Alnylam Pharmaceuticals INC. | $26.57 | 2022 | |
| Arthrex, INC. | $24.00 | 2025 | |
| Genentech USA, INC. | $22.99 | 2024 | Venclexta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $19.39 | 2022 | |
| Deciphera Pharmaceuticals INC. | $19.21 | 2023 | Qinlock |
| Amarin Pharma, INC. | $18.10 | 2020 | |
| Kls-Martin L.P. | $17.07 | 2023 | |
| Ethicon INC. | $14.70 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.87 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,506,472.41 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.